Answers are grounded in this paper and cite their sources.
Meeting abstracts Adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TILs) achieved impressive clinical results in several single institution Phase I/II clinical trials performed outside of Europe, and holds the promise to enter the mainstream of standard melanoma care in the near
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: